JP6587756B2 - 免疫毒素およびチェックポイント阻害剤の併用療法 - Google Patents
免疫毒素およびチェックポイント阻害剤の併用療法 Download PDFInfo
- Publication number
- JP6587756B2 JP6587756B2 JP2018543049A JP2018543049A JP6587756B2 JP 6587756 B2 JP6587756 B2 JP 6587756B2 JP 2018543049 A JP2018543049 A JP 2018543049A JP 2018543049 A JP2018543049 A JP 2018543049A JP 6587756 B2 JP6587756 B2 JP 6587756B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tumor
- checkpoint inhibitor
- immunotoxin
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002637 immunotoxin Effects 0.000 title claims description 69
- 229940051026 immunotoxin Drugs 0.000 title claims description 69
- 239000002596 immunotoxin Substances 0.000 title claims description 69
- 231100000608 immunotoxin Toxicity 0.000 title claims description 69
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims description 62
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims description 62
- 238000002648 combination therapy Methods 0.000 title description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 95
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 34
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 34
- 206010018338 Glioma Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 21
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 claims description 17
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 13
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 12
- 101150030083 PE38 gene Proteins 0.000 claims description 12
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 12
- 150000003384 small molecules Chemical class 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000029824 high grade glioma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000011614 malignant glioma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 38
- 238000000034 method Methods 0.000 description 25
- 238000009097 single-agent therapy Methods 0.000 description 20
- 208000032612 Glial tumor Diseases 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 238000007920 subcutaneous administration Methods 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000005809 anti-tumor immunity Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 102000001301 EGF receptor Human genes 0.000 description 11
- 108060006698 EGF receptor Proteins 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 208000005017 glioblastoma Diseases 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000007917 intracranial administration Methods 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000011284 combination treatment Methods 0.000 description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 5
- 102000017578 LAG3 Human genes 0.000 description 5
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000011272 standard treatment Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- 101150030213 Lag3 gene Proteins 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 230000005746 immune checkpoint blockade Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000005923 long-lasting effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
- 102100026882 Alpha-synuclein Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 3
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 3
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- BNVPFDRNGHMRJS-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 BNVPFDRNGHMRJS-UHFFFAOYSA-N 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- -1 CGEN-15049 Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000000220 brain stem cancer Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- JUPOTOIJLKDAPF-UHFFFAOYSA-N n-[3-cyclopropyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C(C5CC5)=NN(CC=5N=C(C)C=CC=5)C=4C=CC=3)N2C=C1 JUPOTOIJLKDAPF-UHFFFAOYSA-N 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Description
本発明は免疫療法の領域に関する。特に、本発明は、腫瘍を治療するための併用レジメンと、それらを達成するためのキットおよび医薬とに関する。
神経膠芽腫は、全ての原発性の脳および中枢神経系腫瘍のうちで最も恐ろしい悪性脳腫瘍である。現在の標準の治療でのまたはさらに新規に開発された薬剤での神経膠芽腫患者の生存期間中央値は15ヶ月未満である。したがって、神経膠芽腫の患者の低い生存の見通しならびにEGFR受容体を発現する他の腫瘍を改善するために、高度で効果的な治療方法を開発する差し迫った必要性がある。
[本発明1001]
患者における腫瘍を治療する方法であって、以下の段階を含む、方法:
PE38短縮型シュードモナス(Pseudomonas)外毒素に融合された単鎖可変領域抗体を含む免疫毒素を前記患者に投与する段階であって、単鎖可変領域抗体が配列番号6〜11に示されるCDR1、CDR2、およびCDR3領域を有する、段階;および
前記患者に免疫チェックポイント阻害剤を投与する段階。
[本発明1002]
前記腫瘍が悪性神経膠腫である、本発明1001の方法。
[本発明1003]
前記腫瘍が乳がんである、本発明1001の方法。
[本発明1004]
前記腫瘍が頭頚部扁平上皮細胞がんである、本発明1001の方法。
[本発明1005]
前記腫瘍が肺がんである、本発明1001の方法。
[本発明1006]
前記免疫毒素が前記腫瘍に直接投与される、本発明1001の方法。
[本発明1007]
前記免疫チェックポイントが、PD−1、PD−L1、CTLA−4、LAG−3、TIM−3、およびCSF−1Rからなる群から選択される、本発明1001の方法。
[本発明1008]
前記チェックポイント阻害剤が抗PD−1抗体である、本発明1001の方法。
[本発明1009]
前記チェックポイント阻害剤が抗PD−L1抗体である、本発明1001の方法。
[本発明1010]
前記チェックポイント阻害剤が抗CTLA4抗体である、本発明1001の方法。
[本発明1011]
前記チェックポイント阻害剤が抗LAG−3抗体である、本発明1001の方法。
[本発明1012]
前記チェックポイント阻害剤が抗TIM−3抗体である、本発明1001の方法。
[本発明1013]
前記チェックポイント阻害剤が抗CSF−1R抗体である、本発明1001の方法。
[本発明1014]
前記チェックポイント阻害剤がIDOの小分子阻害剤である、本発明1001の方法。
[本発明1015]
前記チェックポイント阻害剤がCSF−1Rの小分子阻害剤である、本発明1001の方法。
[本発明1016]
前記免疫チェックポイント阻害剤が前記免疫毒素の投与の30日以内に投与される、本発明1001の方法。
[本発明1017]
前記免疫チェックポイント阻害剤が前記免疫毒素の投与の7日以内に投与される、本発明1001の方法。
[本発明1018]
前記PE38短縮型シュードモナス外毒素がKDELペプチドに融合されている、本発明1001の方法。
[本発明1019]
腫瘍を治療するためのキットであって、以下を含む、キット:
PE38短縮型シュードモナス外毒素に融合された単鎖可変領域抗体を含む免疫毒素であって、単鎖可変領域抗体が配列番号6〜11に示されるCDR1、CDR2、およびCDR3領域を有する、免疫毒素;および
免疫チェックポイント阻害剤。
[本発明1020]
前記チェックポイント阻害剤が抗PD−1抗体である、本発明1019のキット。
[本発明1021]
前記チェックポイント阻害剤が抗PDL−1抗体である、本発明1019のキット。
[本発明1022]
前記チェックポイント阻害剤が抗CTLA4抗体である、本発明1019のキット。
[本発明1023]
前記チェックポイント阻害剤が抗LAG−3抗体である、本発明1019のキット。
[本発明1024]
前記チェックポイント阻害剤が抗TIM−3抗体である、本発明1019のキット。
[本発明1025]
前記チェックポイント阻害剤が抗CSF−R1抗体である、本発明1019のキット。
[本発明1026]
前記チェックポイント阻害剤がIDOの小分子阻害剤である、本発明1019のキット。
[本発明1027]
前記チェックポイント阻害剤がCSF−R1の小分子阻害剤である、本発明1019のキット。
[本発明1028]
前記PE38短縮型シュードモナス外毒素がKDELペプチドに融合されている、本発明1019のキット。
発明者らは、D2C7モノクローナル抗体(mAb)由来の単鎖可変フラグメント(scFv)を、任意でKDELペプチドと融合される、シュードモナス外毒素A(PE)と融合することにより、標的指向免疫毒素(IT)、即ちD2C7−(scdsFv)−PE38KDEL(D2C7−IT)を開発した。D2C7−ITは、野生型上皮成長因子受容体(EGFRwt)およびEGFR変異体III(EGFRvIII)の両方(これら2つのタンパク質は神経膠芽腫で過剰発現している)と反応する。D2C7−ITの強力な抗腫瘍有効性は、免疫不全マウスでの同所性神経膠腫異種移植片モデルにおいてPEにより仲介される。直接的な腫瘍細胞死滅に加えて、免疫毒素単独療法は、T細胞の関与により二次抗腫瘍免疫応答を誘発する。免疫毒素が免疫チェックポイント阻害剤とともに併用レジメンで投与される場合、改善された相乗的な結果が観察される。
本発明者らは、マウス神経膠腫細胞系、即ち、D2C7−IT抗原であるマウスEGFRvIII(mEGFRvIII)を過剰発現するCT−2A−mD2C7を確立した。CT−2A−mD2C7細胞に対するD2C7−ITの反応性および治療有効性を、それぞれフローサイトメトリーおよびインビトロ細胞傷害性アッセイ(WST1)によって決定した。CT−2A−mD2C7細胞をフローサイトメトリーによりMHCクラスIおよびPD−L1発現について更に分析した。D2C7−ITもしくはαCTLA−4もしくはαPD−1の単独療法またはD2C7−IT+αCTLA−4もしくはD2C7−IT+αPD−1の併用療法のインビボ有効性を、皮下CT−2A−mD2C7神経膠腫保持C57BL/6免疫適格性マウスにおいて評価した。
フローサイトメトリー分析によって、D2C7モノクローナル抗体のCT−2A−mD2C7細胞への特異的結合能を確認した(図2D)。フローサイトメトリーはまた、腫瘍細胞表面上のMHCクラスI分子(図2Aおよび図2B)およびPD−L1(図2C)の両方の高発現も示した。D2C7−ITは、インビトロWST1細胞傷害性アッセイにおいてCT−2A−mD2C7細胞に対して高度に細胞傷害性(IC50=0.47ng/mL)であった(図3)。
D2C7−(scdsFv)−PE38KDEL免疫毒素の構築、発現、および精製。D2C7 VHドメインのカルボキシル末端を、15アミノ酸ペプチド(Gly4Ser)3リンカーによってVLドメインのアミノ末端に繋げた。安定なITを得るために、再生中にVHがVLの近くに確実に位置していることが必須である。このことは、安定化ジスルフィド結合を形成させるために、各鎖中の単一の重要な残基をシステインへと突然変異させることで達成した。分子モデリングを用いる予測および他のdsFv組み換えITでの経験的データに基づいて、本発明者らは、各鎖において、システインへと突然変異させるアミノ酸を1つ選んだ。これらは、VHのフレームワーク領域2(FR2)中の残基44およびVLのFR4中の残基100である(Kabatの番号付けに従う)。このようにして、本発明者らは、ペプチドリンカーと、VHのSer44およびVLのGly100を置き換えるシステイン残基によって生じるジスルフィド結合との両方を含むFvを準備した。D2C7(scdsFv)PCR断片を次にシュードモナス外毒素AのドメインIIおよびIIIのDNAに融合した。ここで使用したシュードモナス外毒素AのバージョンであるPE38KDELは、改変されたC末端を有し、このC末端はPE38KDELの細胞内保持を増大し、ひいてはその細胞傷害性を増強する。D2C7−(scdsFv)−PE38KDELを、T7プロモーターの制御下で、大腸菌内で発現させ、封入体として回収した。
神経膠芽腫の治療のための腫瘍標的化および腫瘍関連マクロファージ:本発明者らは、免疫適格性神経膠芽腫マウスモデルにおいて、相乗的に機能し効果的な抗腫瘍応答を生じるD2C7−ITおよびBLZ945の併用処置の能力を評価した。
皮下(SC)CT2A−mD2C7神経膠腫モデルにおけるD2C7−IT+(抗CTLA4または抗PD1)阻害剤組み合わせ療法のインビボ有効性
前の試験的研究において、本発明者らは、皮下再チャレンジマウス神経膠腫同種移植片がこれらの腫瘍内(i.t.)免疫毒素療法によって治癒されたSCマウス神経膠腫同種移植片を保持する免疫適格性マウスにおいて拒絶されたことを観察し、このことは、SC免疫毒素療法の後の記憶抗腫瘍免疫応答が存在し得ることを示唆する。この現象は、IL−13を標的とする免疫毒素によって処置されたSC黒色腫マウスモデルにおいても報告されており、ここで黒色腫は、CNSにおける悪性神経膠腫と比較して非常に異なる腫瘍型であるが、CTLはこの免疫毒素誘発抗腫瘍応答を媒介するのに主要な役割を果たしている。したがって、長く持続する寛解を達成するために、神経膠芽腫に対する免疫毒素によって誘発される二次免疫応答を研究するための適当なマウス神経膠腫モデルを確立することが必要であり、かつ抗CTLA4または抗PD1抗体(αCTLA4またはαPD1)等の免疫チェックポイント阻害剤の組み合わせ療法によってこの応答を増強する方法を決定することが必要である。
D2C7−ITおよび免疫チェックポイント阻害剤の組み合わせ処置群からの治癒マウスについての腫瘍再チャレンジ研究
D2C7−ITおよび免疫チェックポイント阻害剤の組み合わせ処置群からの治癒マウスが、防御的抗腫瘍記憶免疫応答を想起し得るかどうか決定するために、最初の腫瘍チャレンジ後72日目に、9匹の治癒マウスすべてに対し、次いで、左側腹部において106個の用量のCT2A親細胞で最初に皮下に再チャレンジ(1°SCR)した。これらのマウスはすべて、mD2C7陰性腫瘍を拒絶したが、未処置ナイーブマウスすべてにおいて腫瘍は成長し、組み合わせ処置が、mD2C7陰性親細胞にも及んだ、長く持続する抗腫瘍免疫をもたらしたことを示唆する(図9A)。
両側皮下CT2A−mD2C7神経膠腫モデルにおけるD2C7−IT+(抗CTLA4または抗PD1)阻害剤組み合わせ療法のインビボ有効性
インビボ両側皮下CT2A−mD2C7神経膠腫モデルにおいて、腫瘍細胞を、C57BL/6マウスにて両側の側腹部内に同時に、右側では高い密度(3×106細胞)で、左側では低い密度(106細胞)で接種した。大きい方の腫瘍(右側)を、D2C7−ITもしくはαCTLA4もしくはαPD1の単独療法またはD2C7−IT+αCTLA4もしくはD2C7−IT+αPD1の併用療法(免疫チェックポイント阻害剤を免疫毒素療法と同じ日に投与した)の4回の投与(2日おき)で処置し、一方で左側の腫瘍は未処置であった。D2C7−IT単独療法(高用量、1回の投与あたりマウス1匹につき4.5μg、腫瘍内)、D2C7−IT+αCTLA4(1回の投与あたりマウス1匹につき100μg、腹腔内)、およびD2C7−IT+αPD1(1回の投与あたりマウス1匹につき250μg、腹腔内)組み合わせ療法は、右側の腫瘍の有意な成長遅延をもたらし(P<0.01)、それぞれ4/10、6/10、および5/10の右側の腫瘍を治癒した(図10A)。
Claims (21)
- PE38短縮型シュードモナス(Pseudomonas)外毒素に融合された単鎖可変領域抗体を含む免疫毒素であって、単鎖可変領域抗体が配列番号6〜11に示されるCDR1、CDR2、およびCDR3領域を有する、免疫毒素;ならびに
抗PD−1抗体、抗PD−L1抗体、抗CTLA4抗体、およびCSF−1Rの小分子阻害剤BLZ945からなる群より選択される免疫チェックポイント阻害剤
を組み合わせてなる、腫瘍を治療するための医薬。 - PE38短縮型シュードモナス(Pseudomonas)外毒素に融合された単鎖可変領域抗体を含む免疫毒素であって、単鎖可変領域抗体が配列番号6〜11に示されるCDR1、CDR2、およびCDR3領域を有する、免疫毒素を含み、
抗PD−1抗体、抗PD−L1抗体、抗CTLA4抗体、およびCSF−1Rの小分子阻害剤BLZ945からなる群より選択される免疫チェックポイント阻害剤と併用される、
腫瘍を治療するための医薬。 - 抗PD−1抗体、抗PD−L1抗体、抗CTLA4抗体、およびCSF−1Rの小分子阻害剤BLZ945からなる群より選択される免疫チェックポイント阻害剤を含み、
PE38短縮型シュードモナス(Pseudomonas)外毒素に融合された単鎖可変領域抗体を含む免疫毒素であって、単鎖可変領域抗体が配列番号6〜11に示されるCDR1、CDR2、およびCDR3領域を有する、免疫毒素と併用される、
腫瘍を治療するための医薬。 - 前記腫瘍が悪性神経膠腫である、請求項1〜3のいずれか一項に記載の医薬。
- 前記腫瘍が乳がんである、請求項1〜3のいずれか一項に記載の医薬。
- 前記腫瘍が頭頚部扁平上皮細胞がんである、請求項1〜3のいずれか一項に記載の医薬。
- 前記腫瘍が肺がんである、請求項1〜3のいずれか一項に記載の医薬。
- 前記免疫毒素が前記腫瘍に直接投与されるように用いられることを特徴とする、請求項1〜7のいずれか一項に記載の医薬。
- 前記チェックポイント阻害剤が抗PD−1抗体である、請求項1〜8のいずれか一項に記載の医薬。
- 前記チェックポイント阻害剤が抗PD−L1抗体である、請求項1〜8のいずれか一項に記載の医薬。
- 前記チェックポイント阻害剤が抗CTLA4抗体である、請求項1〜8のいずれか一項に記載の医薬。
- 前記チェックポイント阻害剤がCSF−1Rの小分子阻害剤BLZ945である、請求項1〜8のいずれか一項に記載の医薬。
- 前記免疫チェックポイント阻害剤が前記免疫毒素の投与の30日以内に投与されるように用いられることを特徴とする、請求項1〜12のいずれか一項に記載の医薬。
- 前記免疫チェックポイント阻害剤が前記免疫毒素の投与の7日以内に投与されるように用いられることを特徴とする、請求項1〜12のいずれか一項に記載の医薬。
- 前記PE38短縮型シュードモナス外毒素がKDELペプチドに融合されている、請求項1〜14のいずれか一項に記載の医薬。
- 腫瘍を治療するためのキットであって、以下を含む、キット:
PE38短縮型シュードモナス外毒素に融合された単鎖可変領域抗体を含む免疫毒素であって、単鎖可変領域抗体が配列番号6〜11に示されるCDR1、CDR2、およびCDR3領域を有する、免疫毒素;ならびに
抗PD−1抗体、抗PD−L1抗体、抗CTLA4抗体、およびCSF−1Rの小分子阻害剤BLZ945からなる群より選択される免疫チェックポイント阻害剤。 - 前記チェックポイント阻害剤が抗PD−1抗体である、請求項16に記載のキット。
- 前記チェックポイント阻害剤が抗PD−L1抗体である、請求項16に記載のキット。
- 前記チェックポイント阻害剤が抗CTLA4抗体である、請求項16に記載のキット。
- 前記チェックポイント阻害剤がCSF−R1の小分子阻害剤BLZ945である、請求項16に記載のキット。
- 前記PE38短縮型シュードモナス外毒素がKDELペプチドに融合されている、請求項16〜20のいずれか一項に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562250749P | 2015-11-04 | 2015-11-04 | |
US62/250,749 | 2015-11-04 | ||
PCT/US2016/060469 WO2017079520A1 (en) | 2015-11-04 | 2016-11-04 | Combination therapy of immunotoxin and checkpoint inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018533626A JP2018533626A (ja) | 2018-11-15 |
JP6587756B2 true JP6587756B2 (ja) | 2019-10-09 |
Family
ID=58662982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018543049A Active JP6587756B2 (ja) | 2015-11-04 | 2016-11-04 | 免疫毒素およびチェックポイント阻害剤の併用療法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11065332B2 (ja) |
EP (2) | EP3973988A1 (ja) |
JP (1) | JP6587756B2 (ja) |
CN (2) | CN116327955A (ja) |
WO (1) | WO2017079520A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110115767A (zh) * | 2018-02-05 | 2019-08-13 | 美国安吉益民公司 | 免疫调节剂联合检查点抑制剂治疗癌症的方法 |
WO2019195302A1 (en) * | 2018-04-02 | 2019-10-10 | Duke University | Neoadjuvant cancer treatment |
WO2019222504A1 (en) * | 2018-05-16 | 2019-11-21 | Duke University | Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination |
WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
WO2021087105A1 (en) * | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
WO2023279095A1 (en) * | 2021-07-01 | 2023-01-05 | Duke University | D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA197264A (en) | 1920-02-17 | K. Kosich Demster | Fruit picker | |
CA154291A (en) | 1913-10-21 | 1914-03-10 | A. Edwin Aldred | Packing |
EP1606285A4 (en) | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | IDO INHIBITORS AND METHODS OF USE THEREOF |
FR2926560A1 (fr) | 2008-01-21 | 2009-07-24 | Millipore Corp | Procede d'extraction et de purification d'acides nucleiques sur membrane |
US20090269343A1 (en) | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
US7994662B2 (en) | 2009-06-23 | 2011-08-09 | Anorad Corporation | Thermal block and thermal rail |
JP5589077B2 (ja) * | 2009-07-20 | 2014-09-10 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ |
AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
EP2704713B1 (en) | 2011-05-05 | 2017-01-18 | Novartis AG | Csf-1r inhibitors for treatment of brain tumors |
WO2015035112A1 (en) * | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
WO2015069770A1 (en) * | 2013-11-05 | 2015-05-14 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
-
2016
- 2016-11-04 JP JP2018543049A patent/JP6587756B2/ja active Active
- 2016-11-04 EP EP21193555.6A patent/EP3973988A1/en active Pending
- 2016-11-04 US US15/773,418 patent/US11065332B2/en active Active
- 2016-11-04 CN CN202211240353.XA patent/CN116327955A/zh active Pending
- 2016-11-04 CN CN201680070875.6A patent/CN108367070B/zh active Active
- 2016-11-04 EP EP16863025.9A patent/EP3370773B1/en active Active
- 2016-11-04 WO PCT/US2016/060469 patent/WO2017079520A1/en active Application Filing
-
2021
- 2021-07-15 US US17/376,319 patent/US20210338811A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN116327955A (zh) | 2023-06-27 |
US20210338811A1 (en) | 2021-11-04 |
US11065332B2 (en) | 2021-07-20 |
EP3973988A1 (en) | 2022-03-30 |
WO2017079520A1 (en) | 2017-05-11 |
CN108367070A (zh) | 2018-08-03 |
EP3370773B1 (en) | 2022-01-05 |
EP3370773A1 (en) | 2018-09-12 |
US20180311346A1 (en) | 2018-11-01 |
EP3370773A4 (en) | 2019-05-29 |
CN108367070B (zh) | 2022-10-28 |
JP2018533626A (ja) | 2018-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6587756B2 (ja) | 免疫毒素およびチェックポイント阻害剤の併用療法 | |
EP3353212B1 (en) | Optimized anti-cd3 bispecific antibodies and uses thereof | |
JP5960597B2 (ja) | 癌治療のための併用免疫療法 | |
JP7369297B2 (ja) | Cd47、pd-l1に特異的な抗体、およびその使用 | |
US20200079860A1 (en) | Methods and compositions for tumor therapy | |
JP2021510082A (ja) | 改変オルトポックスウイルスベクター | |
Khan et al. | Licensed monoclonal antibodies and associated challenges | |
US20230141413A1 (en) | Immunotherapy with combination therapy comprising an immunotoxin | |
KR20240038991A (ko) | 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합 | |
CA2987436C (en) | Modified hyaluronan and uses thereof in cancer treatment | |
CN112423778A (zh) | 利用免疫毒素和检查点抑制剂组合的新辅助癌症治疗 | |
US20240010696A1 (en) | IL-12 Variants and Uses Thereof | |
TW202409067A (zh) | Il-12變體、抗pd1抗體、融合蛋白及其用途 | |
EA040594B1 (ru) | Оптимизированные биспецифические анти-cd3 антитела и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180530 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180605 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180605 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190513 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190814 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190814 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190910 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6587756 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |